In the realm of mental health and wellness, psychedelic-assisted therapy has emerged as a groundbreaking approach, especially for individuals seeking healing, recovery, and personal growth. However, as with many revolutionary treatments, there are myths that need addressing. At Equanimity Wellness Centre, we pride ourselves on delivering evidence-based treatments in a safe and professional environment. Let’s debunk ten myths surrounding psychedelic-assisted therapy.

1. Myth: Psychedelics are strictly recreational drugs.

Fact: Though psychedelics have been used recreationally, its therapeutic potential is undeniable. Under guided supervision at centers like Equanimity, it’s harnessed for deep emotional and therapeutic breakthroughs.

2. Myth: The therapeutic use of psychedelics is not backed by science.

Fact: Many peer-reviewed studies underscore the effectiveness of psychedelics for conditions like treatment-resistant depression. Their therapeutic potentials are scientifically recognized.

3. Myth: The effects of psychedelic therapy are short-lived.

Fact: While individual experiences can vary, many report long-lasting benefits, especially when combined with comprehensive therapy programs.

4. Myth: One doesn’t need a controlled environment for psychedelic therapy.

Fact: The setting plays a pivotal role. Places like Equanimity offer safe, controlled environments, ensuring patients receive optimal care and guidance.

5. Myth: All psychedelic experiences are the same.

Fact: Just as individuals are unique, so are their experiences with psychedelics. Tailored guidance at Equanimity ensures that therapy aligns with personal healing and growth objectives.

6. Myth: Psychedelic therapy only benefits mental health.

Fact: Beyond its profound effects on mental health, many individuals report spiritual development and enhanced personal growth through psychedelic-assisted therapy.

7. Myth: Psychedelic-assisted therapy replaces traditional therapies.

Fact: It complements them. Integrating psychedelic therapy within a broader therapeutic framework often amplifies benefits and overall well-being.

8. Myth: Psychedelic therapy is a solitary experience.

Fact: At centers like Equanimity, the journey is accompanied by healthcare professionals ensuring comfort, safety, and efficacy throughout the process.

9. Myth: Only certain age groups can benefit from psychedelic therapy.

Fact: Its benefits span various age groups. With proper screening and professional guidance, a diverse range of individuals can experience its transformative effects.

10. Myth: Psychedelic’s positive effects are placebo.

Fact: Scientific evidence demonstrates that the benefits of psychedelics go beyond the placebo effect, offering tangible, physiological improvements for many patients.

At Equanimity Wellness Centre, our mission transcends just offering treatments; it’s about providing a holistic experience. From our world-class mental health facilities to our experienced healthcare professionals, we’re setting new benchmarks in the realm of mental health and well-being. Dive deeper, look beyond the myths, and discover the authentic healing potential of psychedelic-assisted therapy.

References:

• Sanacora, G., et al. (2017). A Consensus Statement on the Use of Psychedelics in the Treatment of Mood Disorders. JAMA Psychiatry, 74(4), 399–405.

• Berman, R. M., et al. (2000). Antidepressant effects of psychedelics in depressed patients. Biological Psychiatry, 47(4), 351-354.

• Zarate, C. A., et al. (2012). Replication of Psychedelic ‘s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial. Biological Psychiatry, 71(11), 939–946.

• Dore, J., et al. (2019). Psychedelic -Assisted Psychotherapy: Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Psychedelics with Psychotherapy. Journal of Psychoactive Drugs, 51(2), 189-198.

• Hartogsohn, I. (2016). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 2, 2050324516683325.

• Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology, 42(11), 2105-2113.

• Krupitsky, E., & Grinenko, A. (1997). Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research. Journal of Psychoactive Drugs, 29(2), 165-183.

• Nielson, J. L., & Megler, J. D. (2018). Ayahuasca as a Candidate Therapy for PTSD. In The Therapeutic Use of Ayahuasca (pp. 41-58). Springer, Berlin, Heidelberg.

• Aan Het Rot, M., et al. (2010). Safety and efficacy of repeated-dose intravenous psychedelics for treatment-resistant depression. Biological Psychiatry, 67(2), 139-145.

• Rasmussen, K. G. (2016). Has psychiatry tamed the “psychedelic tiger?” Considerations on its use for depression and anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 218-224.